Pathos AI signs major ADC partnership with Chinese biotech Alphamab and targets up to $300M Series E raise

Pathos AI, a technology and drug development company, announced a major antibody‑drug conjugate (ADC) collaboration with Chinese biotech Alphamab.

The firm also disclosed a partnership with AstraZeneca, though specific details were not provided.

Pathos AI said it will launch a Series E financing round that could raise up to $300 million, valuing the company at roughly $3 billion.

These moves illustrate the company’s aggressive push to expand its pipeline and secure substantial funding.